After excluding GEN1 from the analysis, the WGS data identified six individuals in the BRCA1/2 cohort with LoF PPVs in four dominant cancer-associated genes, in addition to their clinically diagnosed BRCA1/2 mutation (Table 2 and Fig. 1C). This evidence concerns the gene BRCA1 and cancer.